content top

A New 23 Gauge Vitrectomy System

George A. Williams, MD (Royal Oak, MI)* PURPOSE: A new 23 gauge vitrectomy system based on the Acurus platform has been developed to enhance the advantages of sutureless transconjunctival vitrectomy while minimizing the disadvantages. METHODS: This 23 gauge system employs a single pass, transconjunctival cannula system which creates selfsealing pars plana entry site wounds. The larger instrumentation compared to 25 gauge decreases...

Read More

Response of Different Patterns of Diabetic Macular Edema to Treatment with a Sustained-release Dexamethasone Posterior-segment Drugdelivery System

Baruch D. Kuppermann, MD, PhD (Irvine, CA),* Connie Chou, PhD (Irvine, CA),* David V. Weinberg, MD (Milwaukee, WI),* Scott M. Whitcup, MD (Irvine, CA),* Julia A. Haller, MD (Baltimore, MD),* Mark S. Blumenkranz, MD (Stanford, CA),* George A. Williams, MD (Royal Oak, MI)* PURPOSE: To evaluate the response of different patterns of persistent diabetic macular edema (DME) unresponsive to prior medical or laser therapy to treatment with a novel...

Read More

Two-year Efficacy and Safety Results from the MARINA Study

http://www.evrs.eu/medias/2006/congress/Two-year-Efficacy-and-Safety-Results-from-the-MARINA-Study.swf Ursula Schmidt-Erfurth, MD (Vienna, Austria), George A.Williams, MD (Royal Oak, MI), for the MARINA Study Group PURPOSE: The MARINA study is a 2-year, Phase III, multicenter, randomized, double-masked, sham injectioncontrolled study designed to evaluate the efficacy and safety of monthly intravitreal injections of ranibizumab used as a...

Read More
content top